MCID: PLM021
MIFTS: 35

Pilomyxoid Astrocytoma malady

Categories: Neuronal diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Pilomyxoid Astrocytoma

About this section
Sources:
10Disease Ontology, 12DISEASES, 51Orphanet, 65UMLS, 42NCIt, 59SNOMED-CT, 66UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Pilomyxoid Astrocytoma:

Name: Pilomyxoid Astrocytoma 10 12 51 65

Characteristics:

Orphanet epidemiological data:

51
pilomyxoid astrocytoma:
Inheritance: Not applicable; Age of onset: All ages

Classifications:



External Ids:

Disease Ontology10 DOID:4845
NCIt42 C40315
SNOMED-CT59 388600004
Orphanet51 251615
UMLS via Orphanet66 C1519086
UMLS65 C1519086

Summaries for Pilomyxoid Astrocytoma

About this section
MalaCards based summary: Pilomyxoid Astrocytoma is related to pilocytic astrocytoma and pineal gland astrocytoma. An important gene associated with Pilomyxoid Astrocytoma is COL1A1 (Collagen Type I Alpha 1), and among its related pathways are Osteoblast Signaling and pilocytic astrocytoma. Affiliated tissues include brain, breast and skeletal muscle, and related mouse phenotypes are pigmentation and tumorigenesis.

Related Diseases for Pilomyxoid Astrocytoma

About this section

Graphical network of the top 20 diseases related to Pilomyxoid Astrocytoma:



Diseases related to pilomyxoid astrocytoma

Symptoms for Pilomyxoid Astrocytoma

About this section

Drugs & Therapeutics for Pilomyxoid Astrocytoma

About this section

Drugs for Pilomyxoid Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
CyproheptadineapprovedPhase 315129-03-32913
Synonyms:
1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine
1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
129-03-3
4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine
4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine
41354-29-4
5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-20-08-00500 (Beilstein Handbook Reference)
AC1L1ER8
AKOS004119847
Axoprol
BIDD:GT0324
BPBio1_000096
BPBio1_000155
BRD-K28143534-001-01-4
BRD-K28143534-003-03-6
BRN 1685976
BSPBio_000086
Biomol-NT_000131
C06935
CAS-969-33-5
CCRIS 5232
CHEBI:4046
CHEMBL516
CID2913
CYPROHEPTADINE
Ciproheptadina
Ciproheptadina [INN-Spanish]
Ciprovit
Ciprovit (TN)
Cypoheptadine
Cyproheptadiene
Cyproheptadin
Cyproheptadine
Cyproheptadine (INN)
 
Cyproheptadine Hcl
Cyproheptadine Hydrochloride
Cyproheptadine [INN:BAN]
Cyproheptadinum
Cyproheptadinum [INN-Latin]
D07765
DB00434
Dibenzosuberonone/Cyproheptadine
Dihexazin
Dronactin
EINECS 204-928-9
Eiproheptadine
Glutodina
HMS2090P20
HSDB 3048
L001016
LS-114933
Lopac-C-6022
Lopac0_000246
MK 141
MolPort-002-507-777
NCGC00015252-01
NCGC00015252-02
NCGC00015252-03
NCGC00015252-09
NCGC00024293-02
NCGC00024293-04
NCGC00024293-05
Oprea1_498140
PDSP1_001229
PDSP2_001213
Periactin
Periactine
Periactinol
Prestwick0_000103
Prestwick1_000103
Prestwick2_000103
Prestwick3_000103
SPBio_002025
STK802098
Tocris-0996
UNII-2YHB6175DO
Viternum
nchembio.559-comp10
2
Histamine PhosphateapprovedPhase 390651-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
 
H0147
Histamine Positive Skin Test Control
Histamine Positive skin test control
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
3Anti-Allergic AgentsPhase 31312
4
SerotoninPhase 3314750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
5Serotonin AgentsPhase 32668
6Serotonin AntagonistsPhase 31175
7Histamine H1 AntagonistsPhase 3688
8Neurotransmitter AgentsPhase 314795
9Histamine AntagonistsPhase 3826
10AntipruriticsPhase 3619
11Dermatologic AgentsPhase 34555
12Gastrointestinal AgentsPhase 36401
13
histaminePhase 390675614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
14
Irinotecanapproved, investigationalPhase 1, Phase 2104497682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
15
CarboplatinapprovedPhase 1, Phase 2188541575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
16
MebendazoleapprovedPhase 1, Phase 22231431-39-74030
Synonyms:
(5-Benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester
(5-Benzoyl-1H-benzimidazol-2-yl)carbamic acid methyl ester
(5-Benzoyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester
(5-benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester
2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester
2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester (8CI)
31431-39-7
46404_FLUKA
46404_RIEDEL
5-Benzoyl-2-benzimidazolecarbamic acid methyl ester
5-Benzoyl-2-benzimidazolecarbamic acid, methyl ester
AB00052203
AC-12064
AC1L1H98
AC1Q44DR
AKOS000539066
Abello Farmacia Brand of Mebendazole
Anti Worm
Anti-Worm
Ardeypharm Brand of Mebendazole
BAS 00341140
BIDD:GT0087
BPBio1_000257
BRD-K77987382-001-01-7
BRD-K77987382-001-06-6
BSPBio_000233
BSPBio_003178
Bantenol
Banworm
Besantin
Bio-0458
Bio-0803
Boots Brand of Mebendazole
Boots Threadworm Treatment
CAS-31431-39-7
CBDivE_010559
CCRIS 4479
CHEBI:6704
CHEMBL685
CID4030
CPD000036734
Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester
Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester (9CI)
Carbamic acid, N-(5-benzoylbenzimidazol-2-yl)-, methyl ester
D00368
D008463
DB00643
Degort's Brand of Mebendazole
Diba Brand of Mebendazole
DivK1c_000751
EINECS 250-635-4
Elfar Brand of Mebendazole
Equivurm Plus
Esteve Brand of Mebendazole
HMS1536H11
HMS1568L15
HMS1921F03
HMS2090B03
HMS2092B15
HMS502F13
HSDB 3232
Healthypharm Brand of Mebendazole
I06-2075
IDI1_000751
Janssen Brand of Mebendazole
KBio1_000751
KBio2_001778
KBio2_004346
KBio2_006914
KBio3_002398
KBioGR_000712
KBioSS_001778
LS-48951
Leidapharm Brand of Mebendazole
Lomper
M2523_FLUKA
M2523_SIGMA
MBDZ
MEBENDAZOLE, 99%
MLS000028491
Madicure
Mebendan
Mebendazol
Mebendazol [INN-Spanish]
Mebendazole
Mebendazole (JAN/USP)
 
Mebendazole (JAN/USP/INN)
Mebendazole [USAN:INN:BAN:JAN]
Mebendazole(USAN)
Mebendazolum
Mebendazolum [INN-Latin]
Mebenoazole
Mebenvet
Mebex
Mebutar
Methyl 5-benzoyl benzimidazole-2-carbamate
Methyl 5-benzoyl-2-benzimidazolecarbamate
Methyl 5-benzoyl-2-benzimidazolylcarbamate
Methyl N-(5-benzoyl-1H-benzimidazol-2-yl)carbamate
Methyl N-(5-benzoyl-2-benzimidazolyl)carbamate
MolPort-000-765-625
MolPort-001-889-615
Mébendazole
N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle
N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle [French]
N-2 (5-Benzoyl-benzimidazole) carbamate de methyle
N-2 (5-Benzoyl-benzimidazole) carbamate de methyle [French]
NCGC00016806-01
NCGC00016806-02
NCGC00021698-03
NCGC00021698-04
NCGC00021698-05
NCGC00021698-06
NINDS_000751
NSC 184849
NSC184849
Norgine Brand of Mebendazole
Noverme
Oprea1_278237
Oprea1_768530
Ovitelmin
Pantelmin
Pfizer Brand of Mebendazole
Prestwick0_000217
Prestwick1_000217
Prestwick2_000217
Prestwick3_000217
Prestwick_310
Pripsen Mebendazole
Probes1_000013
Probes2_000149
R 17,635
R 17635
R-17635
R17635
SAM002548959
SMR000036734
SPBio_001442
SPBio_002154
SPECTRUM1501110
SSL Brand of Mebendazole
STK093862
Spectrum2_001401
Spectrum3_001439
Spectrum4_000416
Spectrum5_001381
Spectrum_001298
Sqworm
Streger Brand of Mebendazole
Sufil
Surfont
TL8002405
Taxandria Brand of Mebendazole
Tedec Meiji Brand of Mebendazole
Telmin
TimTec1_000869
UNII-81G6I5V05I
Vermicidin
Vermicol
Vermidil
Vermin
Vermirax
Vermox
Vermox (TN)
Verpanyl
Versid
Wormkuur
ZINC00121541
mebendazole
methyl (5-benzoyl-1H-benzimidazol-2-yl)carbamate
methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate
methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate
methyl [5-(phenylcarbonyl)-1H-benzimidazol-2-yl]carbamate
17
CetuximabapprovedPhase 1, Phase 2713205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
 
Cetuximab (genetical recombination) (JAN)
D03455
Erbitux
Erbitux (TN)
IMC-C225
cetuximab
18
Vincristineapproved, investigationalPhase 1, Phase 28632068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
19
Temozolomideapproved, investigationalPhase 1, Phase 266285622-93-15394
Synonyms:
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide
3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
85622-93-1
AC-758
AC1L1K9B
BIDD:GT0204
BRN 5547136
Bio-0147
C047246
C6H6N6O2
CCRG 81045
CCRG-81045
CCRIS 8996
CHEBI:153686
CHEMBL810
CID5394
CPD000466338
D06067
DB00853
Essex brand of temozolomide
HMS2051O12
HMS2090B08
I06-0149
I14-1943
LS-80558
M B 39831
M & B 39831
M&B 39831
M&B-39831
 
M-39831
MB 39831
MLS000759447
MLS001424028
MLS002701861
Methazolastone
NCGC00167429-01
NCGC00167429-02
NCI60_003316
NSC 362856
NSC-362856
NSC362856
SAM001246636
SMR000466338
STK623541
Sch 52365
Sch-52365
Schering brand of temozolomide
Schering-Plough brand of temozolomide
TL8005593
TMZ
TMZ-Bioshuttle
Temodal
Temodal (TN)
Temodar
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
Temozolomide
Temozolomide (JAN/USAN/INN)
Temozolomide [INN:BAN]
Temozolomidum
Temozolomidum [Latin]
Témozolomide
UNII-YF1K15M17Y
ZINC01482184
m & b 39831
temozolomide
20
PiperazineapprovedPhase 1, Phase 222110-85-04837
Synonyms:
1,4-Diazacyclohexane
1,4-Diethylenediamine
1,4-Piperazine
110-85-0
14007-05-7 (unspecified hydrobromide)
142-63-2 (hexahydrate)
142-64-3 (di-hydrochloride)
14538-56-8 (phosphate[1:1])
16832-43-2 (unspecified hydrate)
1951-97-9 (unspecified phosphate)
3597-26-0 (unspecified sulfate)
5-23-01-00030 (Beilstein Handbook Reference)
6094-40-2 (unspecified hydrochloride)
7542-23-6 (mono-hydrochloride)
8017-90-1
8027-81-4
8057-14-5 (unspecified salt)
80621_FLUKA
854880-15-2
861800-35-3
AB1003720
AC1L1J2E
AC1Q1IA7
AC1Q1IA8
AC1Q1IA9
AKOS000269028
AR-1L1009
ARONIS23910
Anthalazine
Antiren
Asca-Trol No. 3
BIDD:GT0273
BRN 0102555
C07973
CCRIS 5950
CHEBI:28568
CHEMBL1412
CID4837
D00807
DB00592
Diethylenediamine
Diethyleneimine
Dispermine
DivK1c_000038
EINECS 203-808-3
Eraverm
Eraverm (VAN)
Fluphenazine dihydrochloride
HMS1920H20
HMS2092A03
HMS500B20
HSDB 1093
Hexahydro-1,4-diazine
Hexahydropyrazine
I14-11172
IDI1_000038
InChI=1/C4H10N2/c1-2-6-4-3-5-1/h5-6H,1-4H
Jsp000824
KBio1_000038
KBio2_001593
KBio2_004161
KBio2_006729
KBioSS_001593
LS-517
LTBB000432
Lumbrical
MolPort-000-872-010
NCGC00094762-01
NCGC00094762-02
NCIOpen2_000984
NCIOpen2_000988
NCIOpen2_001024
NCIOpen2_001031
NCIOpen2_001033
NCIOpen2_001071
NCIOpen2_001073
 
NCIOpen2_001111
NCIOpen2_001151
NCIOpen2_001231
NCIOpen2_001262
NCIOpen2_001269
NCIOpen2_004830
NCIOpen2_004834
NCIOpen2_004862
NCIOpen2_004874
NCIOpen2_004904
NCIOpen2_004910
NCIOpen2_004914
NCIOpen2_004942
NCIOpen2_004952
NCIOpen2_004954
NCIOpen2_004982
NCIOpen2_004992
NCIOpen2_004994
NCIOpen2_005022
NCIOpen2_005032
NCIOpen2_005034
NCIOpen2_005062
NCIOpen2_005072
NCIOpen2_005102
NCIOpen2_005108
NCIOpen2_005145
NCIOpen2_005182
NCIOpen2_005185
NCIOpen2_005187
NCIOpen2_005200
NCIOpen2_005575
NCIOpen2_005980
NCIOpen2_009422
NINDS_000038
NSC 474
NSC474
P0446
P0447
P45907_SIAL
PIPERAZINE (HEXAHYDRATE)
PZE
Piperazidine
Piperazin
Piperazin [German]
Piperazin [Germany]
Piperazine
Piperazine (USP)
Piperazine Dihydrochloride Dihydrochloride Hydrate
Piperazine Hexa-Hydrate
Piperazine [UN2579] [Corrosive]
Piperazine [UN2579] [Corrosive]
Piperazine [USAN]
Piperazine anhydrous
Piperazine citrate
Piperazine hexahydrate
Piperazine hydrate
Piperazine, anhydrous
Pipersol
Pyrazine hexahydride
Pyrazine, hexahy
SPECTRUM1500490
Spectrum5_001817
Spectrum_001113
UN2579
UNII-1RTM4PAL0V
Upixon
Uvilon
Vermex
Vermizine
Vermizine (TN)
Vermizine (tn)
WLN: T6M DMTJ
Worm-A-Ton
Worm-away
Wurmirazin
nchembio814-comp12
piperazine
piperazinium oleate
21
Bevacizumabapproved, investigationalPhase 1, Phase 21875216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
22
CrizotinibapprovedPhase 1, Phase 292877399-52-511626560, 10366136, 10366137, 10366138, 10366139, 10366140, 10366141
Synonyms:
(R)-Crizotinib
C-Met/HGFR Tyrosine Kinase Inhibitor PF-02341066
C-Met/Hepatocyte Growth Factor Receptor Tyrosine Kinase Inhibitor PF-02341066
Crizotinib
Crizotinibum
 
MET Tyrosine Kinase Inhibitor PF-02341066
PF 2341066
PF-02341066
PF-2341066
Xalkori
crizotinib
23topoisomerase I inhibitorsPhase 1, Phase 21131
24Angiogenesis Modulating AgentsPhase 1, Phase 23611
25Antineoplastic Agents, PhytogenicPhase 1, Phase 24294
26Angiogenesis InhibitorsPhase 1, Phase 23688
27Alkylating AgentsPhase 1, Phase 23582
28Piperazine citratePhase 1, Phase 222
29Tubulin ModulatorsPhase 1, Phase 24279
30Topoisomerase InhibitorsPhase 1, Phase 24081
31Antiparasitic AgentsPhase 1, Phase 21854
32Antimitotic AgentsPhase 1, Phase 24296
33AnthelminticsPhase 1, Phase 2379
34Anti-Infective AgentsPhase 1, Phase 217220
35AnticonvulsantsPhase 1, Phase 22249
36Antineoplastic Agents, AlkylatingPhase 1, Phase 23406
37Protein Kinase InhibitorsPhase 1, Phase 23162
38CitrateNutraceuticalPhase 1, Phase 21001
39
Citric AcidnutraceuticalPhase 1, Phase 2100177-92-9311
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
Chemfill
Citraclean
 
Citrate
Citretten
Citric acid
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
40
TrioxsalenapprovedPhase 1403902-71-45585
Synonyms:
2',4,8-Trimethylpsoralen
4,5',8-Trimethylpsoralen
4,8,5'-Trimethylpsoralen
6-Hydroxy-beta,2,7-trimethyl-5-benzofuranacrylic acid, delta-lactone
Trimethylpsoralen
Trioxisaleno
 
Trioxsalen
Trioxysalen
Trioxysalene
Trioxysalenum
Trisoralen
trimethylpsoralen
trioxysalen
trisoralen
41
Verteporfinapproved, investigationalPhase 183129497-78-55362420
Synonyms:
Verteporfin
Verteporfina
 
Verteporfinum
Vertéporfine
Visudyne
42Dihematoporphyrin EtherPhase 140
43
Octreotideapproved, investigational19883150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
 
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Ocphyl
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide acetate
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatin
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
44Edotreotide20
45Radiopharmaceuticals362
46Fluorides364
47Dihydroxyphenylalanine123

Interventional clinical trials:

idNameStatusNCT IDPhase
1Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for CancerTerminatedNCT01132547Phase 3
2A Phase I Study of Mebendazole for the Treatment of Pediatric GliomasRecruitingNCT01837862Phase 1, Phase 2
3Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22RecruitingNCT01884740Phase 1, Phase 2
4Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell LymphomaActive, not recruitingNCT00939770Phase 1, Phase 2
5Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or LymphomaCompletedNCT01273090Phase 1
6Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain TumorsRecruitingNCT00002647Phase 1
7Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain TumorsSuspendedNCT02194452
818F FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly Diagnosed or Recurrent GliomasTerminatedNCT02175745

Search NIH Clinical Center for Pilomyxoid Astrocytoma

Genetic Tests for Pilomyxoid Astrocytoma

About this section

Anatomical Context for Pilomyxoid Astrocytoma

About this section

MalaCards organs/tissues related to Pilomyxoid Astrocytoma:

33
Brain, Breast, Skeletal muscle, Lung, Prostate, Testis

Animal Models for Pilomyxoid Astrocytoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Pilomyxoid Astrocytoma:

38 (show all 11)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.5COL1A1, NF1, PTPN11, SUFU, TP53
2MP:00020069.1COL1A1, MGMT, NF1, PTPN11, SUFU, TP53
3MP:00053718.9COL1A1, COL2A1, NF1, PDGFRB, PTPN11, SUFU
4MP:00053818.7COL1A1, COL2A1, NF1, PDGFRB, PTPN11, SUFU
5MP:00053828.7COL1A1, COL2A1, NF1, PDGFRB, PTPN11, SUFU
6MP:00053808.5COL1A1, COL2A1, KDR, NF1, PDGFRB, PTPN11
7MP:00053758.4COL1A1, COL2A1, KIAA1549, PDGFRB, PTPN11, SUFU
8MP:00053918.3COL1A1, COL2A1, KDR, NF1, PDGFRB, PTPN11
9MP:00107718.0COL1A1, DACT2, KDR, NF1, PDGFRB, PTPN11
10MP:00028737.7COL1A1, COL2A1, KDR, NF1, PDGFRB, PTPN11
11MP:00036317.4COL1A1, COL2A1, KDR, NF1, PDGFRB, PTPN11

Publications for Pilomyxoid Astrocytoma

About this section

Articles related to Pilomyxoid Astrocytoma:

(show top 50)    (show all 59)
idTitleAuthorsYear
1
Estimation of changes in the force of infection for intestinal and urogenital schistosomiasis in countries with schistosomiasis control initiative-assisted programmes. (26499981)
2015
2
Effects of deletion of mutant huntingtin in steroidogenic factor 1 neurons on the psychiatric and metabolic phenotype in the BACHD mouse model of Huntington disease. (25271967)
2014
3
Statin use may improve clinicopathological characteristics and recurrence risk of invasive breast cancer. (24381143)
2014
4
Assessing the relationship of paraoxonase-1 Q192R polymorphisms and the severity of lung disease in SM-exposed patients. (23672526)
2013
5
Controlling highly pathogenic avian influenza, Bangladesh. (23171830)
2012
6
Screening of congenital cytomegalovirus infection by real-time PCR in urine pools. (21614511)
2012
7
Time trends in epidemiology of peptic ulcer disease in India over two decades. (22766645)
2012
8
AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation. (21057547)
2011
9
Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome. (21423218)
2011
10
Endoscopic treatment of maxillary inverted papilloma. (21858271)
2011
11
Respiratory onset in an ALS family with L144F SOD1 mutation. (20562451)
2011
12
Prokaryotic taxonomy rules and nomenclature changes in the Mycobacterium chelonae-abscessus group. (21073303)
2010
13
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. (18707986)
2008
14
A minimal binding footprint on CD1d-glycolipid is a basis for selection of the unique human NKT TCR. (18378792)
2008
15
The rate and significance of Mediterranean fever gene mutations in patients with ankylosing spondylitis: a three-month, longitudinal clinical study. (18597091)
2008
16
Human chorionic gonadotropin and alpha-fetoprotein concentrations in pregnancy and maternal risk of breast cancer: a nested case-control study. (18936438)
2008
17
Verapamil attenuates renal tubular apoptosis in response to partial unilateral ureteral obstruction. (18204240)
2008
18
Regulation of cardiac cAMP synthesis and contractility by nucleoside diphosphate kinase B/G protein beta gamma dimer complexes. (17363702)
2007
19
Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. (17971592)
2007
20
Expression of hyaluronan synthase genes in umbilical cord blood stem/progenitor cells. (16564133)
2006
21
Two cases of isolated diffuse mesangial sclerosis with WT1 mutations. (16479084)
2006
22
Focal adhesion kinase is critical for entry of Kaposi's sarcoma-associated herpesvirus into target cells. (16414994)
2006
23
Usage of the new parenteral selective cox-2 inhibitor dynastat in the gynecologic practice]. (17168490)
2006
24
Novel compound heterozygote mutations (H234Q/R1206X) of the ADAMTS13 gene in an adult patient with Upshaw-Schulman syndrome showing predominant episodes of repeated acute renal failure. (16449289)
2006
25
Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. (16849545)
2006
26
Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. (16706971)
2006
27
PTP-1B inhibitors: cyclopenta[d][1,2]-oxazine derivatives. (16289879)
2006
28
Characterization of candidate genes for neuronal ceroid lipofuscinosis in dog. (15958790)
2005
29
Alternatively spliced variants of protocadherin 8 exhibit distinct patterns of expression during mouse development. (15627506)
2005
30
New approaches to development of mucosal vaccine against enteric bacterial pathogens; preventing campylobacteriosis. (15787191)
2004
31
Mitochondrial tRNA(Leu(UUR)) mutation at position 3243 and symptomatic polyneuropathy in type 2 diabetes. (12663619)
2003
32
Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. (11830547)
2002
33
Low levels of productive HIV infection in Langerhans cell-like dendritic cells differentiated in the presence of TGF-beta1 and increased viral replication with CD40 ligand-induced maturation. (11180099)
2001
34
Terminal latency index in polyneuropathy with IgM paraproteinemia and anti-MAG antibody. (11562906)
2001
35
Endurance training, expression, and physiology of LDH, MCT1, and MCT4 in human skeletal muscle. (10751188)
2000
36
Human intestinal es nucleoside transporter: molecular characterization and nucleoside inhibitory profiles. (10755314)
2000
37
Ewing's sarcoma in a patient with congenital optic atrophy. (9856684)
1998
38
Neuron-specific enolase-producing epithelioid leiomyosarcoma with gross vascular invasion and intracardiac involvement. (9870863)
1998
39
Regulation of gene expression in Sertoli cells by follicle-stimulating hormone (FSH): cloning and characterization of LRPR1, a primary response gene encoding a leucine-rich protein. (7758824)
1995
40
The role of MR imaging in the diagnosis of alveolar soft part sarcoma: a report of 10 cases. (7644939)
1995
41
Targeting of the 67-kDa isoform of glutamic acid decarboxylase to intracellular organelles is mediated by its interaction with the NH2-terminal region of the 65-kDa isoform of glutamic acid decarboxylase. (7836456)
1995
42
p53 Overexpression in laryngeal squamous cell carcinoma and dysplasia. (16696005)
1995
43
Primary amyloidosis associated with a novel heavy-chain fragment (AH amyloidosis). (8141123)
1994
44
Cloning and characterization of the bovine immunoglobulin J chain cDNA and its promoter region. (8286037)
1994
45
The homeodomain protein, Pit-1/GHF-1, is capable of binding to and activating cell-specific elements of both the growth hormone and prolactin gene promoters. (2284007)
1990
46
The effect of hydrophobization of glucose-6-phosphate dehydrogenase with progesterone on its thermal inactivation]. (2392417)
1990
47
Co-existing vitiligo and small-plaque parapsoriasis. (3792599)
1986
48
Platelet function in scurvy and experimental human vitamin C deficiency. (7330838)
1981
49
SPELEOTOMY IN RENAL TUBERCULOSIS. (14314112)
1965
50
The Gerstmann syndrome; case report and review of the literature. (20291825)
1947

Variations for Pilomyxoid Astrocytoma

About this section

Expression for genes affiliated with Pilomyxoid Astrocytoma

About this section
Search GEO for disease gene expression data for Pilomyxoid Astrocytoma.

Pathways for genes affiliated with Pilomyxoid Astrocytoma

About this section

Pathways related to Pilomyxoid Astrocytoma according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.9COL1A1, PDGFRB
29.9NF1, PTPN11
39.2MGMT, NF1, PDGFRB, TP53
49.0COL1A1, COL2A1, KDR, PDGFRB, TP53

GO Terms for genes affiliated with Pilomyxoid Astrocytoma

About this section

Biological processes related to Pilomyxoid Astrocytoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1negative regulation of transcription factor import into nucleusGO:004299210.5NF1, SUFU
2collagen fibril organizationGO:003019910.2COL1A1, COL2A1, NF1
3platelet-derived growth factor receptor signaling pathwayGO:004800810.0PDGFRB, PTPN11
4wound healingGO:00420609.8COL1A1, NF1, PDGFRB
5extracellular matrix organizationGO:00301989.3COL1A1, COL2A1, KDR, NF1

Molecular functions related to Pilomyxoid Astrocytoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1vascular endothelial growth factor bindingGO:00380859.6KDR, PDGFRB

Sources for Pilomyxoid Astrocytoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet